Compare the Best Regulatory Affairs Vendors

Who this guide is for

This guide is for biotech founders, heads of clinical development and programme leads deciding who will carry their regulatory work: a strategy consultancy, a CRO with an in-house regulatory team, specialist counsel, or a mix. It matters most before a first-in-human study, a move into new jurisdictions, or a scientific advice meeting. The list above is a starting point, not a verdict. It shows which vendors carry a regulatory or quality profile, the service model and footprint each record lists, and who each profile says it suits. It cannot tell you how a vendor handled a specific submission or how senior its writers are. Vendor scores on Clinical Vendor Compare come only from published platform reviews; a vendor with no reviews shows no score.

What a regulatory affairs vendor does — and when you need one

A regulatory affairs vendor plans and delivers your dealings with medicines regulators. The work splits into two halves that are often sold separately. Regulatory strategy is the thinking: which jurisdiction to open in, what the agency will expect before first dosing, which orphan or expedited pathways might apply, and how to frame questions for scientific advice. Regulatory operations is the execution: compiling and publishing dossiers, managing portal submissions, tracking commitments and keeping the regulatory record consistent through amendments.

The category borders several others. Ethics and IRB services review protocols for participant protection; they do not prepare your clinical trial application. Regulatory information management software stores and tracks submissions but does not write them. Quality vendors run CAPA and audit systems. Law firms advise on interpretation and enforcement risk. A full-service CRO may bundle regulatory start-up with monitoring and data management.

Biotechs usually need outside help at predictable trigger points: a pre-IND or scientific advice briefing package, the first clinical trial application, a new region, a substantial modification, agency questions on CMC, or an end-of-Phase II meeting. With a lean in-house team, those moments arrive faster than hiring can follow.

How to evaluate a regulatory affairs vendor

Strategy depth versus operational capacity

Ask who writes the strategy and who runs the submissions. Some consultancies are strategy-heavy and subcontract publishing; some CROs are the reverse. Request a redacted strategy document, CVs for the named lead and backup, and a written split of in-house versus subcontracted work.

UK: MHRA combined review through IRAS

In the UK, a trial of an investigational medicinal product is reviewed by the MHRA and a research ethics committee together through combined review: one submission via IRAS, one coordinated outcome. The updated UK clinical trials regulations that took effect in 2026 keep that route and add more proportionate, risk-based provisions. If your search began with "regulatory affairs CRO UK", ask how recently the team has run combined review submissions under the new rules and how it handles requests for further information.

EU: Regulation (EU) No 536/2014 and CTIS

Across the EU and EEA, applications go through the Clinical Trials Information System under Regulation (EU) No 536/2014, which has governed all ongoing trials since the transition ended in early 2025. One application covers every Member State concerned: Part I, the scientific and product assessment, is led by a reporting Member State; Part II, covering consent, recruitment and site suitability, is assessed nationally. Ask how the vendor meets request-for-information deadlines, since a missed response can lapse the application.

US: the IND and FDA meetings

In the US, clinical investigation of a new drug or biologic needs an Investigational New Drug application under 21 CFR Part 312, which takes effect thirty days after FDA receipt unless the agency imposes a clinical hold. Pre-IND meetings, usually Type B, and the informal INTERACT route for novel products regulated by CBER let you test plans first. Ask which meeting packages the team has written recently.

Scientific advice and briefing documents

EMA offers scientific advice and, for designated orphan medicines, protocol assistance; the MHRA and other national agencies offer their own. Strong vendors write briefing documents that pose answerable questions, state a sponsor position for each, and follow through so the advice changes the development plan. Ask to see a redacted briefing book and the advice it produced.

CMC and quality writing

For many biotechs the hardest questions concern chemistry, manufacturing and controls. The quality section of an IND, and the Investigational Medicinal Product Dossier for UK and EU applications, must describe a product that is still evolving. Ask whether CMC writers are in-house, whether they know your modality, and how they work with your manufacturer and Qualified Person.

Publishing: eCTD versus portal submissions

Not every submission is eCTD. FDA requires eCTD for commercial INDs, and marketing applications to EMA and the MHRA use it, but CTIS and IRAS take structured portal entries plus uploaded documents. Ask which publishing tool the vendor uses, how validation errors are caught before dispatch, and whether you keep a portable copy of every sequence.

Full-service CRO, boutique consultancy or counsel

Full-service CROs fold regulatory start-up into a wider contract, simplifying governance but sometimes queuing regulatory work behind monitoring. Boutiques offer senior attention but may lack publishing capacity or regional reach. Counsel suits policy, enforcement or contested interpretation, not routine authoring. The best regulatory affairs consultancy for biotech clinical trials is the one whose model fills the gap in your team.

Regulatory affairs vendors at a glance

The table sets this guide's vendors side by side on profile fields: vendor type, service model, footprint, headquarters, study phases and therapeutic focus. Use it to sort providers by kind before comparing firms.

Read honestly, the table shows a mixed category: a specialist CRO in Allucent, an IRB and site technology provider in Advarra, a content and compliance platform in Ennov Clinical, practices profiled around FDA advice, legal counsel and global compliance, a digital transformation offer, a CAPA and deviation management offer and a dosage-form QA partner. Treat blank cells as questions, not evidence. All fields come from each vendor's CVC profile.

Vendor profiles

Advarra

Advarra's profile lists an IRB, consent, CTMS and site technology provider offering a regulatory and site technology stack, with global coverage, a US headquarters and Phase I to Phase IV work. It is profiled as best for studies needing electronic data capture and trial workflow tools. Listed strengths include independent IRB review, integrated site CTMS and regulatory credibility with FDA and OHRP. Where to probe: IRB coverage is described as primarily North American, so confirm how UK and EU ethics review fits.

Ennov Clinical

Ennov Clinical is profiled as an eTMF, QMS and regulatory information management vendor with a content and compliance platform, global reach and a French headquarters, best for sponsors needing workflow and study management infrastructure. Listed strengths are a unified platform spanning eTMF, QMS, safety and regulatory, configurable workflows, and submission and dossier management. Where to probe: the profile flags implementation complexity for organisations with legacy systems, so ask for a migration plan.

Allucent

Allucent is profiled as a specialist CRO combining clinical, regulatory and pharmacovigilance services, with global coverage, a US headquarters and Phase I to Phase IV work in generalist and rare disease programmes. Its scale is mid-size programmes and emerging biotech portfolios, with full-service support from early stage to post-approval for biotech and small-to-mid pharma. Where to probe: ask who leads regulatory strategy versus start-up operations, and whether UK and EU submissions are run by local staff.

Accenture (Life Sciences)

Accenture (Life Sciences) is listed as a regulatory and QA provider with global coverage and a generalist profile. Its stated best fit is sponsors wanting digital regulatory transformation. Where to probe: ask whether the offer scales to a single biotech programme, whether it extends to authoring clinical trial applications, how much is delivered by regulatory specialists rather than technology consultants, and how new submission tooling would be validated before go-live.

Akin Gump (FDA Practice)

Akin Gump (FDA Practice) is listed as a regulatory and QA provider with global coverage and a generalist profile. Its stated best fit is sponsors wanting FDA policy and regulatory counsel, relevant when questions turn on interpretation, agency policy or enforcement exposure. Where to probe: confirm how counsel coordinates with whoever compiles and publishes your IND, how advice is scoped and billed, and whether UK and EU matters are covered.

Alston & Bird (FDA)

Alston & Bird (FDA) is profiled as a regulatory and QA provider with global coverage and a generalist therapeutic focus. Its stated best fit is sponsors needing FDA regulatory advisory. Where to probe: ask which FDA interactions the team supports, such as pre-IND questions, clinical hold responses or expedited programme requests, how quickly it can turn round advice before a meeting, and which provider you would pair it with for operational publishing.

Arnold & Porter (Life Sciences)

Arnold & Porter (Life Sciences) is listed as a regulatory and QA provider with global coverage and a generalist profile. Its stated best fit is sponsors wanting regulatory and compliance legal counsel, which a biotech typically uses alongside, not instead of, an operational regulatory team. Where to probe: ask which jurisdictions the life sciences team advises on directly, expected turnaround before agency deadlines, and how fees are structured for a single programme.

AssurX (Quality)

AssurX (Quality) is profiled as a regulatory and QA provider with global coverage and a generalist focus. Its stated best fit is sponsors wanting CAPA and deviation management. Where to probe: confirm whether the offer is software, services or both, how the system is validated for GxP use, and whether its audit trails meet 21 CFR Part 11 expectations.

Baker McKenzie (Life Sciences)

Baker McKenzie (Life Sciences) is listed as a regulatory and QA provider with global coverage and a generalist profile. Its stated best fit is multi-national sponsors needing global regulatory compliance, relevant once a biotech plans trials across regions. Where to probe: ask whether advice comes from local teams in each jurisdiction you need, including the UK and the EU Member States concerned, and how it hands off to the people preparing your applications.

Lonza (Capsugel)

Lonza (Capsugel) is profiled as a regulatory and QA provider with global coverage, a Swiss headquarters, Phase I to Phase III work, a multi-therapeutic focus and small to medium trial scale. Its stated best fit is sponsors needing QA for dosage form development, with listed strengths in dosage form development, capsule-based drug delivery and bioavailability enhancement. That places it on the CMC side of regulatory work. Where to probe: ask how its development data will be packaged for the quality section of your IND or IMPD.

Engagement and pricing models

Regulatory support is bought in a few ways. Project-based fixed fees suit defined deliverables such as a scientific advice briefing package, an IND or a first clinical trial application. Retainers or FTE-based arrangements suit ongoing lifecycle work such as modifications, safety updates and agency correspondence. CROs often bundle regulatory start-up into a wider contract, priced per country or submission; counsel usually bills time.

The main cost drivers are the number of jurisdictions, the novelty of the modality, the maturity of your CMC data, the volume of agency questions and the seniority of the team. Publishing and portal management are often priced apart from writing, and translations for EU Part II documents add cost sponsors underestimate. The trade-off is control: fixed fees can breed scope disputes when unexpected questions arrive, while time-based fees reward a tight brief. Agree a change-order process in writing before you sign.

Questions to put in your RFP

• Who is the named regulatory lead, who is the backup, and how much of the work will they personally deliver?
• Which IRAS combined review submissions has your team prepared under the updated UK regulations, and how did you handle requests for further information?
• How do you manage CTIS user roles, request-for-information deadlines and transparency redactions?
• Can you act as, or arrange, an EU legal representative if we have no EU establishment?
• How do you build a pre-IND meeting package, and who attends the meeting with us?
• Are CMC and IMPD writers in-house, and what experience do they have with our modality?
• Which eCTD publishing tool do you use, and do we receive portable copies of every sequence?
• How do you track commitments and keep documents consistent across regions and modifications?
• What is subcontracted, to whom, and how are subcontractors qualified?

Due-diligence red flags

• Senior strategists at the pitch, junior staff on the work, and no named lead in the contract.
• Outdated process knowledge, such as describing separate MHRA and ethics submissions, or EU application routes that predate CTIS.
• No clear owner for CMC writing, or an assumption that the manufacturer will handle the quality section.
• Publishing subcontracted without disclosure or without validated tools.
• Reluctance to share redacted briefing documents.
• Ownership terms that leave dossiers, sequences or correspondence with the vendor when the contract ends.
• Promises about approval timelines or outcomes that no regulator would guarantee.
• No plan for deadlines that cannot slip, such as CTIS responses that lapse an application if missed.

Shortlist on Clinical Vendor Compare

Start in the vendor directory and filter for regulatory, quality and CRO profiles that match your phase and target regions. Put your preferred candidates side by side on the compare page, then use the sponsor RFP to send a brief built from the questions above, so every vendor answers the same things. If you have worked with a regulatory affairs vendor, write a review: first-hand accounts from other sponsors are what make a shortlist like this more useful to the next biotech.